ALFA Finder
16:04 IST
BSE
Other Announcement
Venus Remedies Other Announcement
Venus Remedies relayed social media posts about a SEBI special window for re-lodging physical share transfer requests. The notice carries no monetary event.
Venus Remedies Ltd
- Share price
- ₹1,443.90
- Market cap
- ₹1,930 Cr
- Revenue (annual)
- ₹769.6 Cr
- Net profit (annual)
- ₹102.8 Cr
- P/E (TTM)
- 15.9×Sector 43.8×
- Promoter holding
- 41.76%+0.00% QoQ
- FII holding
- 3.14%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
4 announcements with these filters
18:31 IST
BSE
Financial Results
Venus Remedies Q2 FY27 Results: Net Profit ₹25.6 Cr, Up 27.4% YoY
Venus Remedies Ltd reported revenue from operations of ₹218.8 Cr (+13.5% YoY) and net profit of ₹25.6 Cr (+27.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹25.6 Cr · +27.4% YoY
14:55 IST
BSE
Regulatory Approval
Venus Remedies Regulatory Approval
Venus Remedies Limited secured five marketing authorizations for drugs including Vancomycin and Meropenem across Kazakhstan, Peru, Kuwait, and Argentina. These regulatory approvals expand its global pharmaceutical portfolio.
16:03 IST
BSE
Board Meeting Date
Venus Remedies Board Meeting Date
Venus Remedies will hold a board meeting on 26th October 2026 to consider and approve its unaudited standalone and consolidated financial results for the September quarter.